AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of USD 15.002 billion, representing 12.4% growth on a reported basis. The strong performance was led by robust growth in the immunology portfolio (+16.4%) and neuroscience segment (+26.0%), offsetting declines in aesthetics and continued Humira erosion in international markets.
Financial Highlights – Q1 2026
Metric
Q1 2026
YOY Change
Worldwide Net Revenues
USD 15.002 billion
+12.4%
Immunology Portfolio
USD 7.290 billion
+16.4%
Neuroscience Portfolio
USD 2.875 billion
+26.0%
Oncology Sales
USD 1.631 billion
-0.2%
Aesthetics Portfolio
USD 1.186 billion
-7.6%
Immunology Portfolio Performance
Product
Q1 2026 Revenue
YOY Change
Skyrizi (risankizumab)
USD 4.483 billion
+30.9%
Rinvoq (upadacitinib)
USD 2.119 billion
+23.3%
Humira (adalimumab)
USD 688 million
-38.6%
Total Immunology
USD 7.290 billion
+16.4%
Key Dynamics
Skyrizi continues exceptional growth trajectory across psoriasis, psoriatic arthritis, and Crohn’s disease indications
Rinvoq demonstrates sustained momentum in rheumatoid arthritis and atopic dermatitis markets
Humira decline reflects expected biosimilar competition impact outside the U.S., where exclusivity expired in 2023
Neuroscience Portfolio Breakdown
Product
Q1 2026 Revenue
YOY Change
Botox Therapeutic
USD 1.009 billion
+16.5%
Vraylar (cariprazine)
USD 905 million
+18.4%
Ubrelvy (ubrogepant)
USD 339 million
+41.4%
Qulipta (atogepant)
USD 296 million
+53.6%
Total Neuroscience
USD 2.875 billion
+26.0%
Growth Drivers
Migraine franchise shows explosive growth with both Ubrelvy and Qulipta exceeding 40% year-over-year increases
Botox Therapeutic maintains strong growth in chronic migraine, spasticity, and therapeutic applications
Vraylar continues steady expansion in bipolar disorder and schizophrenia markets
Business Segment Analysis
Segment
Performance Summary
Immunology
Core growth engine with Skyrizi and Rinvoq successfully offsetting Humira erosion
Neuroscience
Emerging powerhouse with diversified portfolio across psychiatry, neurology, and migraine
Oncology
Stable performance despite competitive pressures in hematologic malignancies
Aesthetics
Temporary decline likely reflecting seasonal patterns and inventory adjustments
Strategic Implications & Market Outlook
Portfolio Diversification Success: AbbVie’s strategic shift from Humira dependency to multi-franchise model is delivering sustainable growth
Immunology Leadership: Skyrizi and Rinvoq combination positions AbbVie as dominant player in next-generation immunology therapeutics
Neuroscience Expansion: Migraine franchise emergence creates new high-growth pillar complementing established Botox and Vraylar franchises
Financial Resilience: Strong cash flow generation supports continued R&D investment and shareholder returns
Competitive Moat: Proprietary biologics and small molecules with strong clinical differentiation maintain pricing power despite biosimilar pressures
Forward‑Looking Statements This brief contains forward-looking statements regarding financial performance, product growth trajectories, and market dynamics. Actual results may differ due to risks including competitive pressures, regulatory developments, pricing pressures, and market adoption rates for newer products.-Fineline Info & Tech
By Fineline Cube 